Thermo Fisher Scientific to Acquire Phadia, a Global Leader in Allergy and Autoimmunity Diagnostics

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to acquire Phadia, a global leader in allergy and autoimmunity diagnostics, from European private equity firm Cinven, for €2.47 billion (or approximately $3.5 billion) in cash.

Click this link to read the Thermo Fisher Scientific Press Release

5/20/2011

 

As in all diagnostic testing, the diagnosis is made by the physican based on both test results and the patient history.